About ocrelizumab
Anti-CD20 monoclonal antibody
Used for
- Treats relapsing forms of multiple sclerosis in adults.
- Treats primary progressive multiple sclerosis in adults.
Usual adult dose
Intravenous: 600 mg every six months, usually after an initial split dose. Subcutaneous formulation: 920 mg every six months.
Common side effects
- Infusion or injection reactions
- Infections, including respiratory infections
- Reduced antibody levels
- Skin reactions
Important warnings
- Screen for hepatitis B before treatment.
- Check for active infections; delay treatment until resolved.
- Vaccinations may need updating before treatment; avoid live vaccines during treatment and until B-cell recovery.
- Rarely, serious brain infection (PML) can occur.
Pregnancy
May harm a developing baby; effective contraception is recommended during treatment and for six months after the last dose.
Breastfeeding
Limited evidence; discuss benefits and potential risks with a healthcare professional.
Interactions
- Other immune-suppressing medicines may increase infection risk.
- Live vaccines may be unsafe or less effective during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.